Browse SYNPO

Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Cell junction, tight junction Perikaryon Cell projection, dendritic spine Cell junction, synapse, postsynaptic cell membrane, postsynaptic density Cell junction, synapse Note=Localized at the tight junction of cells. In brain, localized to the postsynaptic densities and in the perikarya. Associated with dendritic spines of a subset of synapses.
Domain -
Function

Actin-associated protein that may play a role in modulating actin-based shape and motility of dendritic spines and renal podocyte foot processes. Seems to be essential for the formation of spine apparatuses in spines of telencephalic neurons, which is involved in synaptic plasticity (By similarity).

> Gene Ontology
 
Biological Process GO:0007015 actin filament organization
GO:0030038 contractile actin filament bundle assembly
GO:0031032 actomyosin structure organization
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0043149 stress fiber assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0051017 actin filament bundle assembly
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0061572 actin filament bundle organization
Molecular Function GO:0003779 actin binding
Cellular Component GO:0001725 stress fiber
GO:0005923 bicellular tight junction
GO:0014069 postsynaptic density
GO:0015629 actin cytoskeleton
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0030425 dendrite
GO:0031674 I band
GO:0032432 actin filament bundle
GO:0042641 actomyosin
GO:0043025 neuronal cell body
GO:0043197 dendritic spine
GO:0043204 perikaryon
GO:0043292 contractile fiber
GO:0043296 apical junction complex
GO:0044297 cell body
GO:0044309 neuron spine
GO:0044449 contractile fiber part
GO:0045211 postsynaptic membrane
GO:0060076 excitatory synapse
GO:0070160 occluding junction
GO:0097060 synaptic membrane
GO:0097517 contractile actin filament bundle
GO:0098794 postsynapse
GO:0099572 postsynaptic specialization
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
Reactome -
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SYNPO and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SYNPO in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 3.69; FDR: 0.047 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SYNPO in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1690.587
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9550.598
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.410.746
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0310.939
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0520.985
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0030.999
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6010.16
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5980.701
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.560.756
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9510.642
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7650.56
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4280.000918
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SYNPO in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYNPO. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYNPO. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYNPO.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYNPO. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SYNPO expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SYNPO and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSYNPO
Namesynaptopodin
Aliases KIAA1029
Chromosomal Location5q33.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SYNPO collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.